Evidence map›Paper›PMID 23594855›Full record

ReviewNature reviews. Cancer2013

Iron and cancer: more ore to be mined.

Suzy V Torti, Frank M Torti

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 812 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
812citing papers in PubMed, 2 pooled it
39.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

812 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,596 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Metal dependent regulation of sesquiterpene biosynthesis and redox signalling in Santalum album.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  10. Article
  11. Chelation treatment in a novel sub-toxic multi-metal model in rats.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

752 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Suzy V TortiDepartments of Molecular, Microbial and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA. storti@uchc.edu
Frank M Torti
UConn Health · US

Funding

Ferroportin and Iron HomeostasisR01CA171101 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI TORTI, FRANK M. · 2012 to 2016
$1.7M
Ferritin and Kininogen InteractionR01DK071892 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI TORTI, SUZY V · 2007 to 2011
$1.3M
NCI NIH HHS R01 CA171101NIDDK NIH HHS R01 DK071892NIDDK NIH HHS R01DK071892
6 · The paper itself

Abstract

Iron is an essential nutrient that facilitates cell proliferation and growth. However, iron also has the capacity to engage in redox cycling and free radical formation. Therefore, iron can contribute to both tumour initiation and tumour growth; recent work has also shown that iron has a role in the tumour microenvironment and in metastasis. Pathways of iron acquisition, efflux, storage and regulation are all perturbed in cancer, suggesting that reprogramming of iron metabolism is a central aspect of tumour cell survival. Signalling through hypoxia-inducible factor (HIF) and WNT pathways may contribute to altered iron metabolism in cancer. Targeting iron metabolic pathways may provide new tools for cancer prognosis and therapy.

Indexed as

AnimalsAntineoplastic AgentsCell CycleCell HypoxiaDNAHumansIronIron-Binding ProteinsIron Chelating AgentsMetabolic Networks and PathwaysNeoplasmsSignal TransductionTumor MicroenvironmentAntineoplastic AgentsDNAIronIron-Binding ProteinsIron Chelating Agents

Identifiers

PMID23594855
PMCPMC4036554
OpenAlexW2062107099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.